Farxiga Pregnancy & Lactation Safety: What the Evidence Actually Shows

What Is Dapagliflozin and How Does It Work?

Dapagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class and works by blocking glucose reabsorption in the kidney's proximal convoluted tubule. The net result is roughly 70 to 90 grams of urinary glucose excretion per day, which lowers blood glucose independent of insulin secretion. FDA prescribing information confirms this mechanism.

The SGLT2 Transporter and Why Its Location Matters

SGLT2 is expressed almost exclusively in the S1 segment of the proximal tubule. It handles approximately 90% of filtered glucose reabsorption under normal physiologic conditions. A 2012 pharmacology review in Diabetes Care established that SGLT2 inhibitors exploit this renal-specific expression to lower plasma glucose without stimulating pancreatic beta cells.

Because the mechanism is renal, any drug in this class carries inherent risks for tissues that depend on normal tubular function, including the developing fetal kidney.

Beyond Glucose: Cardio-Renal Effects

Dapagliflozin's benefits extend well beyond glycemic control. SGLT2 inhibition reduces proximal tubular sodium reabsorption, which triggers tubuloglomerular feedback and lowers intraglomerular pressure. The DAPA-CKD trial (N=4,304, NEJM 2020) demonstrated a 39% relative risk reduction in sustained decline of eGFR of 50% or more, end-stage kidney disease, or renal or cardiovascular death versus placebo (hazard ratio 0.61, 95% CI 0.51 to 0.72, P<0.001).

DAPA-HF (N=4,744, NEJM 2019) showed a 26% reduction in the composite of worsening heart failure or cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of whether diabetes was present.

These trials enrolled no pregnant participants. Their data cannot be extrapolated to pregnancy.

FDA Pregnancy Category and Labeling

The current Farxiga prescribing label explicitly states that dapagliflozin should be discontinued when pregnancy is recognized during the second trimester. The second and third trimesters are the critical window because fetal kidneys begin active urine production around weeks 10 to 12 but become the primary contributor to amniotic fluid volume by weeks 18 to 20 onward. The FDA label carries this warning under the Warnings and Precautions section.

Why the Second and Third Trimesters Are Specifically Flagged

Fetal renal development depends on intact tubular function. SGLT2 inhibition in the fetal proximal tubule may disrupt that function during the period when the kidney is actively maturing. A 2019 review in the American Journal of Obstetrics & Gynecology summarized the mechanistic concern: drugs that alter tubular sodium and glucose handling can interfere with normal nephrogenesis and amniotic fluid homeostasis.

Oligohydramnios, abnormally low amniotic fluid, has been reported with other agents that affect fetal renal function (most notably ACE inhibitors and ARBs), and the FDA considers the SGLT2-mediated renal mechanism to carry analogous theoretical risk. The FDA's 2023 drug safety communication provides broader context on the SGLT2 inhibitor safety profile.

First-Trimester Exposure: An Incomplete Picture

The label does not carry the same explicit prohibition for the first trimester, but this reflects a data gap rather than a safety assurance. No adequately powered, controlled human trial has evaluated dapagliflozin exposure during the first 12 weeks of gestation. The ongoing AstraZeneca pregnancy registry collects voluntary reports, but as of the most recent published review the numbers remain too small for definitive conclusions. Clinicians should discontinue the drug as soon as pregnancy is confirmed, regardless of gestational age.

Animal Reproductive Toxicology Data

Animal studies provide the most detailed mechanistic evidence available. Rat and rabbit studies cited in the FDA label showed no teratogenicity at exposures approximating human therapeutic doses during organogenesis. The label notes that at higher multiples of human exposure, rat pups showed increased rates of renal pelvic and tubular dilatations.

Postnatal Renal Effects in Animal Offspring

When dapagliflozin was administered to rats during the period corresponding to late gestation and early lactation (gestation day 6 through postnatal day 21), renal pelvic dilatation was observed in offspring at exposures approximately 15 times the maximum recommended human dose. A nonclinical pharmacology summary referenced in the EMA assessment explains that SGLT2 expression in immature rodent kidneys differs from adult expression, making the developing organ potentially more susceptible to transporter inhibition.

The clinical relevance of these findings to humans is not firmly established, but the consistency of the signal across multiple studies motivated the label restriction.

What Animal Data Cannot Tell Us

Rats and humans differ in renal maturation timing. Rat renal development is more postnatal; human renal development is largely prenatal. This means the rat data may actually underestimate the human fetal risk during the second and third trimesters. A 2020 article in Nephrology Dialysis Transplantation reviewed species differences in renal maturation and cautioned against direct extrapolation from rodent neonatal studies to human fetal risk windows.

Dapagliflozin and Breastfeeding

Dapagliflozin is present in rat milk at concentrations approximately 0.49 times the maternal plasma concentration during the first 10 days postpartum, and at approximately 3 times the maternal plasma concentration in later lactation. The FDA label cites these figures directly.

The Neonatal Kidney Concern

Human neonates continue renal maturation for the first two years of life. The neonatal glomerular filtration rate at birth is approximately 20 mL/min/1.73m2, reaching adult values only by age one to two years. A 2015 Pediatric Nephrology review quantified this developmental trajectory and highlighted that drugs affecting tubular function carry heightened risk in the neonatal period because compensatory mechanisms are immature.

Transfer of dapagliflozin through breast milk could expose neonatal kidneys to SGLT2 inhibition during this vulnerable developmental window. No human lactation pharmacokinetic studies have been published.

Clinical Guidance on Breastfeeding

The FDA label states that breastfeeding is not recommended during treatment with dapagliflozin. LactMed, the NIH database of drugs and lactation, classifies dapagliflozin as a drug to avoid during nursing due to the theoretical renal risk in the infant. This recommendation is not based on observed human infant harm, it reflects the precautionary application of animal data in the absence of human evidence.

Patients who choose to breastfeed after an informed discussion with their physician should use an alternative glucose-lowering agent. Insulin does not transfer to breast milk in clinically meaningful amounts and remains the preferred agent. A 2019 Endocrine Society Clinical Practice Guideline confirms insulin as the first-line pharmacologic treatment for gestational and pregestational diabetes during lactation.

Safe Alternatives During Pregnancy and Lactation

Insulin is the standard of care for glucose management during pregnancy across all major guidelines. The American Diabetes Association's Standards of Care in Diabetes 2024 states: "Insulin is the preferred agent for managing both type 1 and type 2 diabetes in pregnancy."

Insulin in Pregnancy

Multiple insulin formulations have established safety records in pregnancy. NPH insulin and regular insulin carry the longest track records. Insulin lispro (Humalog) and insulin aspart (NovoLog) have demonstrated no increased teratogenicity compared to regular human insulin in randomized trials. A Cochrane review (2016) covering insulin analogues in type 1 diabetes in pregnancy found no significant difference in congenital malformations between rapid-acting analogues and regular insulin.

Insulin does not cross the placenta in physiologically significant amounts because the molecule is too large for most placental transport mechanisms. A 2014 Diabetes Care article confirmed this and noted that insulin antibodies, not insulin itself, are the fraction that may reach the fetus.

Metformin: A Nuanced Choice

Metformin crosses the placenta and reaches fetal circulation. The MiG trial (N=751, BMJ 2008) showed metformin was not associated with increased perinatal complications compared to insulin in gestational diabetes, but 46% of participants required supplemental insulin. Long-term follow-up data from the MiG-TOFU cohort suggested metformin-exposed children had higher body mass index at age nine, though the clinical significance remains debated. Published in BMJ Open Diabetes Research & Care (2018), those findings have not changed consensus recommendations, and many guidelines still consider metformin an acceptable adjunct in gestational diabetes when insulin is declined.

For Heart Failure in Pregnancy

Patients taking dapagliflozin for HFrEF present a more complex clinical scenario. Pregnancy itself increases cardiac output by 30 to 50%, and pre-existing HFrEF substantially raises maternal and fetal morbidity. A 2018 ESC guideline on cardiovascular disease in pregnancy recommends individualized risk assessment by a multidisciplinary cardio-obstetric team. SGLT2 inhibitors are not listed among the approved heart failure therapies in pregnancy; diuretics (used cautiously), beta-blockers, and digoxin carry more established pregnancy data.

For CKD in Pregnancy

Dapagliflozin's renoprotective role in CKD (established in DAPA-CKD) cannot be maintained during pregnancy. Blood pressure control with agents compatible with pregnancy (labetalol, nifedipine, methyldopa) and proteinuria monitoring remain the primary management tools for CKD in pregnant patients. KDIGO 2024 CKD guidelines do not include SGLT2 inhibitors among agents recommended for use during pregnancy.

Pharmacokinetics Relevant to Reproductive Safety

Understanding the drug's pharmacokinetics helps clinicians make decisions around conception timing and drug washout.

Half-Life and Clearance

Dapagliflozin has a terminal half-life of approximately 12.9 hours in healthy adults. Protein binding is approximately 91%. The FDA label pharmacokinetics section indicates that after oral dosing, mean peak plasma concentration occurs at approximately 2 hours. The drug is primarily metabolized by UGT1A9 to an inactive glucuronide metabolite. Five half-lives (approximately 65 hours, or under three days) are sufficient for plasma clearance to below 3% of peak concentration.

Implications for Pre-Conception Counseling

Patients planning pregnancy could theoretically discontinue dapagliflozin three days before attempting conception, allowing full clearance before implantation. This short washout contrasts with drugs like isotretinoin (one-month washout required). In practice, because conception timing is imprecise, the safest approach is to switch to insulin before attempting conception and to confirm pregnancy testing at the earliest possible point. A 2021 pre-conception care consensus statement from the American Diabetes Association recommends optimizing glycemic control with pregnancy-safe agents before conception, not after a positive test.

Special Populations: Gestational Diabetes Diagnosed During Treatment

Some patients are already taking dapagliflozin for type 2 diabetes when gestational diabetes or an unplanned pregnancy is diagnosed. The recommended response is immediate discontinuation upon confirmation of pregnancy, transition to insulin with or without metformin based on glycemic targets, and urgent referral to a maternal-fetal medicine specialist if the patient also has heart failure or CKD.

The following decision framework outlines the transition steps a clinician should take:

1. Confirm pregnancy with serum beta-hCG.
2. Discontinue dapagliflozin on the same day.
3. Initiate basal insulin (NPH or glargine U-100 with obstetric guidance) based on pre-pregnancy total daily dose and current fasting glucose.
4. If the patient has HFrEF or CKD, convene a cardio-obstetric or nephro-obstetric team within 48 to 72 hours.
5. Enroll in the AstraZeneca pregnancy exposure registry (1-800-236-9933) to contribute to prospective safety data.
6. Target fasting glucose <95 mg/dL and 1-hour postprandial glucose <140 mg/dL per ADA 2024 gestational standards.

Monitoring Recommendations During Inadvertent First-Trimester Exposure

Patients who used dapagliflozin through the first trimester before a positive pregnancy test require specific follow-up, not automatic termination counseling. The risk of fetal malformation from first-trimester SGLT2 exposure is not established in humans. A 2022 pharmacovigilance review in Drug Safety analyzed spontaneous reports of SGLT2 inhibitor use in pregnancy across global pharmacovigilance databases and found no clear signal for structural birth defects, though numbers remained small.

Recommended monitoring after inadvertent first-trimester exposure includes:

• Detailed anatomic ultrasound at 18 to 20 weeks to evaluate renal morphology.
• Serial amniotic fluid index measurement starting at 28 weeks.
• Fetal growth ultrasounds every four weeks from 28 weeks onward.
• Neonatal renal function assessment (serum creatinine, urinalysis) at birth.

The Society for Maternal-Fetal Medicine's consultation series on teratogen exposure provides a structured approach to counseling and monitoring after inadvertent drug exposure in pregnancy.

Euglycemic Diabetic Ketoacidosis: An Additional Concern in Pregnancy

SGLT2 inhibitors carry a known risk of euglycemic diabetic ketoacidosis (DKA), ketoacidosis occurring without markedly elevated blood glucose. Pregnancy itself shifts glucose metabolism toward a fat-oxidizing state that raises baseline ketone production. The FDA issued a safety communication on euglycemic DKA with SGLT2 inhibitors in 2015 and updated it in subsequent years. The risk of euglycemic DKA is not specific to dapagliflozin, it applies across the class.

A pregnant patient on dapagliflozin who presents with nausea, vomiting, and malaise should have a stat blood gas and serum ketones ordered even if the glucose reads below 250 mg/dL. Missing euglycemic DKA in pregnancy carries fetal mortality risk. This reinforces the case for discontinuing SGLT2 inhibitors before or immediately upon conception.

What Clinicians Are Saying

The Endocrine Society's 2019 Clinical Practice Guideline on Management of Diabetes in Pregnancy states: "Insulin analogs (rapid-acting and basal) and human insulin are the preferred pharmacological treatments for both type 1 and type 2 diabetes during pregnancy." The guideline makes no provision for SGLT2 inhibitor use in any trimester.

The American College of Obstetricians and Gynecologists Practice Bulletin 201 (2018, reaffirmed 2023) states that "oral hypoglycemic agents other than metformin should generally be avoided in pregnancy due to insufficient safety data." Dapagliflozin falls within that restriction.